The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

The Houthis, an Iranian-backed group based in Yemen, have launched repeated attacks despite the Israeli military’s retaliatory airstrikes. By Adam Rasgon Stepped up attacks by Russia are ...